Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT4 | P35916 | 7/20 | 1.00 |
| ▸ | PDGFRB | P09619 | 6/20 | 1.00 |
| ▸ | FLT3 | P36888 | 5/20 | 1.00 |
| ▸ | CSF1R | P07333 | 2/20 | 0.72 |
| ▸ | EGFR | P00533 | 4/20 | 0.64 |
| ▸ | LCK | P06239 | 1/20 | 0.63 |
| ▸ | AURKA | O14965 | 5/20 | 0.62 |
| ▸ | KDR | P35968 | 5/20 | 0.59 |
| ▸ | FBP1 | P09467 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3430897 | 0.95 | FLT4 (0.91) | FLT4PDGFRBFLT3CSF1REGFR | |
| SCHEMBL2053339 | 0.94 | FLT4 (0.89) | FLT4PDGFRBFLT3CSF1REGFR | |
| SCHEMBL2050438 | 0.94 | FLT4 (0.89) | FLT4PDGFRBFLT3CSF1REGFR | |
| SCHEMBL2053425 | 0.94 | FLT4 (0.89) | FLT4PDGFRBFLT3CSF1REGFR | |
| SCHEMBL3429103 | 0.91 | FLT4 (0.83) | FLT4PDGFRBFLT3CSF1REGFR | |
| SCHEMBL2051229 | 0.90 | FLT4 (0.82) | FLT4PDGFRBFLT3CSF1REGFR | |
| SCHEMBL3431642 | 0.90 | FLT4 (0.82) | FLT4PDGFRBFLT3CSF1REGFR | |
| SCHEMBL2052845 | 0.90 | FLT4 (0.82) | FLT4PDGFRBFLT3CSF1REGFR | |
| SCHEMBL2047693 | 0.90 | FLT4 (0.82) | FLT4PDGFRBFLT3CSF1REGFR | |
| SCHEMBL2048840 | 0.90 | FLT4 (0.82) | FLT4PDGFRBFLT3CSF1REGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1809557-B | Compound | ASTRAZENECA AB | 2012-07-04 | — | — | CN | claimed |
| JP-4709139-B2 | — | — | 2011-06-22 | — | — | JP | claimed |
| US-7691867-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2010-04-06 | — | — | US | claimed |
| EP-1613619-B1 | QUINAZOLINE DERIVATIVES FOR TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2008-03-26 | — | — | EP | claimed |
| US-20060270692-A1 | Chemical compounds | ASTRAZENECA AB (SE) | 2006-11-30 | — | — | US | claimed |
| JP-2006523660-A | — | — | 2006-10-19 | — | — | JP | claimed |
| EP-1613619-A1 | QUINAZOLINE DERIVATIVES FOR TREATMENT OF CANCER | AstraZeneca AB (SE) | 2006-01-11 | — | — | EP | claimed |
| WO-2004094410-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2004-11-04 | — | — | WO | claimed |
| CN-1809557-B | Compound | ASTRAZENECA AB | 2012-07-04 | — | — | CN | disclosed |
| US-7691867-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2010-04-06 | — | — | US | disclosed |
| EP-1613619-B1 | QUINAZOLINE DERIVATIVES FOR TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2008-03-26 | — | — | EP | disclosed |
| US-20060270692-A1 | Chemical compounds | ASTRAZENECA AB (SE) | 2006-11-30 | — | — | US | disclosed |
| EP-1613619-A1 | QUINAZOLINE DERIVATIVES FOR TREATMENT OF CANCER | AstraZeneca AB (SE) | 2006-01-11 | — | — | EP | disclosed |
| WO-2004094410-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2004-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270692-A1 | Chemical compounds | CCNI, MKI67, TP53 | FLT4 2898/4885PDGFRB 1544/4885FLT3 703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.